Abstract 1541
Background. Recombinant human Epo reduces RCTs for anemia of prematurity[1], however it is controversial whether its use should be generally recommended. Objective. To examine whether the data of randomized controlled trials of Epo for anemia of prematurity[1,2] are applicable to our institution where a restrictive standardized RCT protocol (allowing hematocrits of down to 21% in asymptomatic VLBW infants) is strictly followed and Epo is not used. Methods. Between June 1996 and December 1997, all RCTs given to VLBW infants were prospectively recorded. The number of RCT and the total volume of erythrocytes transfused was compared with the reported data of the Epo trials.
Results. (Table)
Conclusions. Following a restrictive RCT protocol without Epo therapy, a RCT rate was achieved similar to that under administration of 750IE-1500IE Epo/week. The impact of RCT guidelines on RCT rates should be considered in the evaluation of Epo trials.
References
Maier et al. N.Engl. J. Med. 1994; 330: 1173–8.
Maier et al. J.Pediatr. 1998; 132: 866–70.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
R, A., Pohlandt, F. Number of Red Cell Transfusions (RCT) in Very Low Birth Weight (VLBW) Infants Using a Standardized Protocol. Is Exogenes Erythropoietin (Epo) Necessary?. Pediatr Res 45, 262 (1999). https://doi.org/10.1203/00006450-199904020-01558
Issue Date:
DOI: https://doi.org/10.1203/00006450-199904020-01558
